DealBio
All collections

Investor Intelligence

10 Drug Delivery Investors in Europe

European investors with demonstrated activity in targeted drug delivery, intracellular transport, RNA delivery and enabling formulation technologies.

Published
  • Drug Delivery
  • Biotechnology
  • RNA Therapeutics
  • Europe
  • Seed
  • Series A

Drug delivery is increasingly investable as a platform layer rather than a single therapeutic category. European financings now span antibody-drug conjugates, intracellular transport, RNA delivery, targeted thrombolysis and technologies that stabilise biological payloads for use outside the cold chain.

DealBio selected 10 investors with evidenced relevance to drug delivery in Europe, using current investor research, financing precedents and public verification where needed.

aMoon Fund

Life-sciences investment firm backing therapeutics and biotechnology companies.

Stage
Series A
Sector / Focus
Drug delivery · Oncology · Antibody therapeutics
Investment markets
France · Europe
Investor type
VC

Relevant investment

aMoon backed Adcytherix, a French clinical-stage antibody-drug-conjugate company. Adcytherix uses antibodies and conjugation chemistry to deliver cancer-drug payloads directly to tumours, providing a direct targeted-delivery precedent.

Surveyor Capital

Investment firm active across biotechnology and healthcare.

Stage
Series A
Sector / Focus
Drug delivery · Oncology · Antibody therapeutics
Investment markets
France · Europe
Investor type
Investment firm

Relevant investment

Surveyor Capital backed Adcytherix, a clinical-stage antibody-drug-conjugate company. The platform links validated cancer-drug payloads to antibodies to target tumours, giving Surveyor a direct drug-delivery and oncology precedent.

Ada Ventures

UK early-stage venture firm investing in technology-led companies.

Stage
Seed · Series A
Sector / Focus
Drug delivery · RNA therapeutics · CNS
Investment markets
United Kingdom · Ireland
Investor type
VC

Relevant investment

Ada Ventures backed Aerska’s seed financing. Aerska is developing RNA medicines for brain disease alongside targeted systemic delivery intended to reach the brain, making the investment directly relevant to both nucleic-acid therapeutics and delivery.

age1

European venture firm focused on healthy longevity and biotechnology.

Stage
Seed
Sector / Focus
Drug delivery · RNA therapeutics · CNS
Investment markets
Ireland · Europe
Investor type
VC

Relevant investment

age1 backed Aerska’s seed round. Aerska combines RNA medicines with a targeted systemic-delivery platform designed for neurological and neurodegenerative disease.

BACKED VC

European early-stage venture firm investing in frontier technology companies.

Stage
Seed
Sector / Focus
Drug delivery · RNA therapeutics
Investment markets
Ireland · Europe
Investor type
VC

Relevant investment

BACKED participated in Aerska’s seed financing. Aerska is building RNA medicines for brain disease together with targeted delivery designed to address the .

BioMedPartners

European healthcare VC investing in biotechnology and medical technology.

Stage
Seed · Series A
Sector / Focus
Drug delivery · Biotechnology
Investment markets
Switzerland · Germany · Europe
Investor type
VC

Relevant investment

BioMedPartners led financing for IDEL Therapeutics, a German biotechnology company developing technology to transport therapeutic payloads into the cell cytosol. The investment gives the fund direct exposure to intracellular drug delivery.

Utrecht Holdings Seed Fund

University-linked seed investor supporting life-sciences companies emerging from Utrecht research.

Stage
Pre-seed · Seed
Sector / Focus
Drug delivery · Biotechnology
Investment markets
The Netherlands
Investor type
Seed fund

Relevant investment

Utrecht Holdings Seed Fund backed NTrans Technologies, which develops technology for bioactive molecules. The platform is designed to move therapeutic cargo across cell membranes, making it a direct enabling-technology precedent for drug delivery.

Andera Partners

European private-markets investor with a dedicated life-sciences strategy.

Stage
Series A
Sector / Focus
Drug delivery · Biotechnology · Therapeutics
Investment markets
France · The Netherlands · Europe
Investor type
VC

Relevant investment

Andera Partners backed TargED Biopharmaceuticals, which develops VHH antibody–enzyme therapeutics that deliver activity directly to clots. Its lead programme targets acute ischemic stroke and other thrombotic diseases, providing a targeted-delivery precedent beyond oncology.

BioGeneration Ventures

European early-stage life-sciences investor focused on company creation and therapeutics.

Stage
Series A
Sector / Focus
Drug delivery · Biotechnology · Therapeutics
Investment markets
The Netherlands · Europe
Investor type
VC

Relevant investment

BioGeneration Ventures backed TargED Biopharmaceuticals. TargED uses antibody–enzyme constructs to localise thrombolytic activity at clots, combining biologic targeting with drug delivery for acute thrombotic disease.

Empirical Ventures

UK early-stage investor focused on deep science and engineering.

Stage
Seed
Sector / Focus
Drug delivery · Biologics · Vaccines
Investment markets
United Kingdom
Investor type
VC

Relevant investment

Empirical Ventures backed EnsiliTech, whose Ensilication platform coats proteins, vaccines and other biological payloads in a silica-based matrix to improve room-temperature stability. The technology is also being explored for mRNA lipid-nanoparticle applications, linking formulation and delivery with reduced cold-chain dependence.

Methodology

DealBio builds investor lists using structured investor research, demonstrated investment activity and current public verification where needed. The methodology highlights investors with evidenced relevance to the article’s sector, stage and geography.

Get the DealBio Pulse

Weekly insights on health and longevity startups, standout founders, key markets, and notable exits.

You can unsubscribe at any time.